Research ArticleConference Proceedings

Aerosolized Antibiotics

Marcos I Restrepo, Holly Keyt and Luis F Reyes
Respiratory Care June 2015, 60 (6) 762-773; DOI: https://doi.org/10.4187/respcare.04208

References

  1. 1.↵
    1. Stockmann C,
    2. Roberts JK,
    3. Yellepeddi VK,
    4. Sherwin CM
    . Clinical pharmacokinetics of inhaled antimicrobials. Clin Pharmacokinet 2015;54(5):473-492.
    OpenUrlPubMed
  2. 2.↵
    1. Hochhaus G,
    2. Horhota S,
    3. Hendeles L,
    4. Suarez S,
    5. Rebello J
    . Pharmacokinetics of orally inhaled drug products. AAPS J 2015;17(3):769-775.
    OpenUrlPubMed
  3. 3.↵
    1. Fink J,
    2. Ari A
    . Aerosol delivery to intubated patients. Expert Opin Drug Deliv 2013;10(8):1077-1093.
    OpenUrlPubMed
  4. 4.↵
    1. Yang JW,
    2. Fan LC,
    3. Lu HW,
    4. Miao XY,
    5. Mao B,
    6. Xu JF
    . Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis. Clin Respir J 2015 [Epub ahead of print] doi: 10.1111/crj.12278.
  5. 5.↵
    1. Konstan MW,
    2. Geller DE,
    3. Minić P,
    4. Brockhaus F,
    5. Zhang J,
    6. Angyalosi G
    . Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46(3):230-238.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Konstan MW,
    2. Flume PA,
    3. Kappler M,
    4. Chiron R,
    5. Higgins M,
    6. Brockhaus F,
    7. et al
    . Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10(1):54-61.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Stephens D,
    2. Garey N,
    3. Isles A,
    4. Levison H,
    5. Gold R
    . Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 1983;2(3):209-211.
    OpenUrlPubMedWeb of Science
  8. 8.↵
    1. Le Brun PP,
    2. Vinks AA,
    3. Touw DJ,
    4. Hekelaar N,
    5. Mannes GP,
    6. Brimicombe RW,
    7. et al
    . Can tobramycin inhalation be improved with a jet nebulizer? Ther Drug Monit 1999;21(6):618-624.
    OpenUrlPubMed
  9. 9.↵
    1. Geller DE,
    2. Konstan MW,
    3. Smith J,
    4. Noonberg SB,
    5. Conrad C
    . Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42(4):307-313.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Langton Hewer SC,
    2. Smyth AR
    . Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009;4:CD004197.
    OpenUrlPubMed
  11. 11.↵
    1. Hoffmann IM,
    2. Rubin BK,
    3. Iskandar SS,
    4. Schechter MS,
    5. Nagaraj SK,
    6. Bitzan MM
    . Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 2002;34(5):375-377.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Gibson RL,
    2. Retsch-Bogart GZ,
    3. Oermann C,
    4. Milla C,
    5. Pilewski J,
    6. Daines C,
    7. et al
    . Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41(7):656-665.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Falagas ME,
    2. Siempos II,
    3. Bliziotis IA,
    4. Michalopoulos A
    . Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit Care 2006;10(4):R123.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Valachis A,
    2. Samonis G,
    3. Kofteridis DP
    . The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med 2015;43(3):527-533.
    OpenUrlPubMed
  15. 15.↵
    1. Stockmann C,
    2. Sherwin CM,
    3. Ampofo K,
    4. Spigarelli MG
    . Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis 2014;8(1):13-21.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Geller DE,
    2. Flume PA,
    3. Staab D,
    4. Fischer R,
    5. Loutit JS,
    6. Conrad DJ
    , Mpex 204 Study Group. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183(11):1510-1516.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Stass H,
    2. Weimann B,
    3. Nagelschmitz J,
    4. Rolinck-Werninghaus C,
    5. Staab D
    . Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther 2013;35(10):1571-1581.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Kollef MH,
    2. Hamilton CW,
    3. Montgomery AB
    . Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis 2013;26(6):538-544.
    OpenUrlPubMed
  19. 19.↵
    1. Ilowite JS,
    2. Gorvoy JD,
    3. Smaldone GC
    . Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987;136(6):1445-1449.
    OpenUrlPubMedWeb of Science
  20. 20.↵
    1. Miller DD,
    2. Amin MM,
    3. Palmer LB,
    4. Shah AR,
    5. Smaldone GC
    . Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med 2003;168(10):1205-1209.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Niederman MS,
    2. Chastre J,
    3. Corkery K,
    4. Fink JB,
    5. Luyt CE,
    6. García MS
    . BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012;38(2):263-271.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Ferrari F,
    2. Liu ZH,
    3. Lu Q,
    4. Becquemin MH,
    5. Louchahi K,
    6. Aymard G,
    7. et al
    . Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med 2008;34(9):1718-1723.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Montgomery AB,
    2. Rhomberg PR,
    3. Abuan T,
    4. Walters KA,
    5. Flamm RK
    . Potentiation effects of amikacin and fosfomycin against selected amikacin-non-susceptible Gram-negative respiratory tract pathogens. Antimicrob Agents Chemother 2014;58(7):3714-3719.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Chalmers JD,
    2. Smith MP,
    3. McHugh BJ,
    4. Doherty C,
    5. Govan JR,
    6. Hill AT
    . Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-665.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Zampieri FG,
    2. Nassar AP Jr.,
    3. Gusmao-Flores D,
    4. Taniguchi LU,
    5. Torres A,
    6. Ranzani OT
    . Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care 2015;19(1):150.
    OpenUrlPubMed
  26. 26.↵
    1. Brodt AM,
    2. Stovold E,
    3. Zhang L
    . Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 2014;44(2):382-393.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Uttley L,
    2. Harnan S,
    3. Cantrell A,
    4. Taylor C,
    5. Walshaw M,
    6. Brownlee K,
    7. Tappenden P
    . Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis. Eur Respir Rev 2013;22(130):476-486.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Lo DK,
    2. Hurley MN,
    3. Muhlebach MS,
    4. Smyth AR
    . Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev 2013;2:CD009650.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Ryan G,
    2. Jahnke N,
    3. Remmington T
    . Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev 2012;12:CD008319.
    OpenUrlPubMed
  30. 30.↵
    1. Falagas ME,
    2. Trigkidis KK,
    3. Vardakas KZ
    . Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: a systematic review. Int J Antimicrob Agents 2015;45(3):221-233.
    OpenUrlPubMed
  31. 31.↵
    1. Máiz L,
    2. Girón RM,
    3. Olveira C,
    4. Quintana E,
    5. Lamas A,
    6. Pastor D,
    7. et al
    . Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother 2013;14(9):1135-1149.
    OpenUrlPubMed
  32. 32.↵
    1. Moss RB
    . Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001;120(3 Suppl):107S-113S.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Mogayzel PJ Jr.,
    2. Naureckas ET,
    3. Robinson KA,
    4. Mueller G,
    5. Hadjiliadis D,
    6. Hoag JB,
    7. et al
    . Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-689.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Murphy TD,
    2. Anbar RD,
    3. Lester LA,
    4. Nasr SZ,
    5. Nickerson B,
    6. VanDevanter DR,
    7. Colin AA
    . Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38(4):314-320.
    OpenUrlCrossRefPubMed
  35. 35.
    1. Nasr SZ,
    2. Sakmar E,
    3. Christodoulou E,
    4. Eckhardt BP,
    5. Streetman DS,
    6. Strouse PJ
    . The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. Pediatr Pulmonol 2010;45(5):440-449.
    OpenUrlPubMed
  36. 36.↵
    1. Gibson RL,
    2. Emerson J,
    3. McNamara S,
    4. Burns JL,
    5. Rosenfeld M,
    6. Yunker A,
    7. et al
    . Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167(6):841-849.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. McCoy KS,
    2. Quittner AL,
    3. Oermann CM,
    4. Gibson RL,
    5. Retsch-Bogart GZ,
    6. Montgomery AB
    . Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178(9):921-928.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Retsch-Bogart GZ,
    2. Quittner AL,
    3. Gibson RL,
    4. Oermann CM,
    5. McCoy KS,
    6. Montgomery AB,
    7. Cooper PJ
    . Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135(5):1223-1232.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Oermann CM,
    2. Retsch-Bogart GZ,
    3. Quittner AL,
    4. Gibson RL,
    5. McCoy KS,
    6. Montgomery AB,
    7. Cooper PJ
    . An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45(11):1121-1134.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Oermann CM,
    2. McCoy KS,
    3. Retsch-Bogart GZ,
    4. Gibson RL,
    5. McKevitt M,
    6. Montgomery AB
    . Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 2011;66(10):2398-2404.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Wainwright CE,
    2. Quittner AL,
    3. Geller DE,
    4. Nakamura C,
    5. Wooldridge JL,
    6. Gibson RL,
    7. et al
    . Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros 2011;10(4):234-242.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Barker AF,
    2. Couch L,
    3. Fiel SB,
    4. Gotfried MH,
    5. Ilowite J,
    6. Meyer KC,
    7. et al
    . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2 Pt 1):481-485.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Dhar R,
    2. Anwar GA,
    3. Bourke SC,
    4. Doherty L,
    5. Middleton P,
    6. Ward C,
    7. Rutherford RM
    . Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010;65(6):553.
    OpenUrlFREE Full Text
  44. 44.↵
    1. Drobnic ME,
    2. Suñé P,
    3. Montoro JB,
    4. Ferrer A,
    5. Orriols R
    . Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39(1):39-44.
    OpenUrlAbstract/FREE Full Text
  45. 45.
    1. Orriols R,
    2. Roig J,
    3. Ferrer J,
    4. Sampol G,
    5. Rosell A,
    6. Ferrer A,
    7. Vallano A
    . Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93(7):476-480.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Scheinberg P,
    2. Shore E
    . A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127(4):1420-1426.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Murray MP,
    2. Govan JR,
    3. Doherty CJ,
    4. Simpson AJ,
    5. Wilkinson TS,
    6. Chalmers JD,
    7. et al
    . A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183(4):491-499.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Barker AF,
    2. O'Donnell A,
    3. Thompson PJ,
    4. Flume PA,
    5. Ruzi J,
    6. Garcia J,
    7. et al
    . Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB). Eur Respir J 2013;42(Suppl 57):P4136.
    OpenUrl
  49. 49.↵
    1. Serisier DJ,
    2. Bilton D,
    3. De Soyza A,
    4. Thompson PJ,
    5. Kolbe J,
    6. Greville HW,
    7. et al
    . Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68(9):812-817.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. White L,
    2. Mirrani G,
    3. Grover M,
    4. Rollason J,
    5. Malin A,
    6. Suntharalingam J
    . Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012;106(3):356-360.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Pasteur MC,
    2. Bilton D,
    3. Hill AT
    , British Thoracic Society Bronchiectasis Non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388-416.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    1. Chastre J,
    2. Fagon JY
    . Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165(7):867-903.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    1. Barbier F,
    2. Andremont A,
    3. Wolff M,
    4. Bouadma L
    . Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013;19(3):216-228.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Hamer DH
    . Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162(1):328-330.
    OpenUrlPubMedWeb of Science
  56. 56.↵
    1. Brown RB,
    2. Kruse JA,
    3. Counts GW,
    4. Russell JA,
    5. Christou NV,
    6. Sands ML
    . Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother 1990;34(2):269-272.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Klick JM,
    2. du Moulin GC,
    3. Hedley-Whyte J,
    4. Teres D,
    5. Bushnell LS,
    6. Feingold DS
    . Prevention of Gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest 1975;55(3):514-519.
    OpenUrlPubMedWeb of Science
  58. 58.↵
    1. Ioannidou E,
    2. Siempos II,
    3. Falagas ME
    . Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007;60(6):1216-1226.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Mandell LA,
    2. Wunderink RG,
    3. Anzueto A,
    4. Bartlett JG,
    5. Campbell GD,
    6. Dean NC,
    7. et al
    . Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-S72.
    OpenUrlFREE Full Text
  60. 60.↵
    1. Arnold HM,
    2. Sawyer AM,
    3. Kollef MH
    . Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 2012;57(8):1226-1233.
    OpenUrlAbstract/FREE Full Text
  61. 61.
    1. Dhariwal AK,
    2. Tullu MS
    . Colistin: re-emergence of the ‘forgotten’ antimicrobial agent. J Postgrad Med 2013;59(3):208-215.
    OpenUrlPubMed
  62. 62.↵
    1. Lu Q,
    2. Yang J,
    3. Liu Z,
    4. Gutierrez C,
    5. Aymard G,
    6. Rouby JJ
    , Nebulized Antibiotics Study Group. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;184(1):106-115.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    1. Palmer LB,
    2. Smaldone GC,
    3. Chen JJ,
    4. Baram D,
    5. Duan T,
    6. Monteforte M,
    7. et al
    . Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008;36(7):2008-2013.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Wood GC
    . Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2011;9(11):993-1000.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Alothman GA,
    2. Alsaadi MM,
    3. Ho BL,
    4. Ho SL,
    5. Dupuis A,
    6. Corey M,
    7. Coates AL
    . Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002;122(3):930-934.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. Nikolaizik WH,
    2. Trociewicz K,
    3. Ratjen F
    . Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 2002;20(1):122-126.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Ramsey BW,
    2. Pepe MS,
    3. Quan JM,
    4. Otto KL,
    5. Montgomery AB,
    6. Williams-Warren J,
    7. et al
    . Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30.
    OpenUrlCrossRefPubMedWeb of Science
  68. 68.↵
    1. Cheer SM,
    2. Waugh J,
    3. Noble S
    . Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003;63(22):2501-2520.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    1. Edson RS,
    2. Brey RH,
    3. McDonald TJ,
    4. Terrell CL,
    5. McCarthy JT,
    6. Thibert JM
    . Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004;79(9):1185-1191.
    OpenUrlCrossRefPubMedWeb of Science
  70. 70.↵
    1. Rubin BK
    . Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008;21(1):71-76.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Prober CG,
    2. Walson PD,
    3. Jones J
    . Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics 2000;106(6):E89.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Palmer LB,
    2. Smaldone GC
    . Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med 2014;189(10):1225-1233.
    OpenUrlPubMed
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords